Literature DB >> 9489590

The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.

H J Feng1, S L Huang, W Wang, H H Zhou.   

Abstract

AIMS: To determine the induction effect of rifampicin on the activity of 4'-hydroxylase in poor metabolizers (PMs) with m1 mutation of S-mephenytoin 4'-hydroxylation and the relationship of the effect with gene dose.
METHODS: Seven extensive metabolizers (EMs) of S-mephenytoin 4'-hydroxylation and five PMs with m1 mutation were chosen to take rifampicin 300 mg day(-1) orally for 22 days. Prior to and after rifampicin treatment, each subject was given racemic mephenytoin 100 mg. The 4'-hydroxymephenytoin (4'-OH-MP) excreted in the 0-24 h urine and mephenytoin S/R ratio in the 0-8 h urine were determined by h.p.l.c. and GC, respectively.
RESULTS: In all EMs, the excretion of 4'-OH-MP in the 0-24 h urine was increased by 146.4 +/- 17.9%, 0-8 h urinary mephenytoin S/R ratio was decreased by 77.3 +/- 8.8%, the percentage increase in the 0-24 h excretion of 4'-OH-MP in those CYP2C19 homozygous (wt/wt) was greater than that in those heterozygous (wt/m1 and wt/m2) (203.9 +/- 42.5% vs 69.6 +/- 4.1%). 0-8 h urinary mephenytoin S/R ratio of those PMs with m1 mutation was decreased by 9.6%, the amount of 4'-OH-MP excreted in the 0-24 h urine was increased by 80.1 +/- 48.0%.
CONCLUSIONS: The activity of 4'-hydroxylase of PMs with m1 mutation of S-mephenytoin 4'-hydroxylation can be induced by rifampicin and the inducing effect of rifampicin on 4'-hydroxylase is gene dependent.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9489590      PMCID: PMC1873992          DOI: 10.1046/j.1365-2125.1998.00643.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Family studies of mephenytoin hydroxylation deficiency.

Authors:  T Inaba; M Jurima; W Kalow
Journal:  Am J Hum Genet       Date:  1986-05       Impact factor: 11.025

2.  Enzyme induction and beta-adrenergic receptor blocking drugs.

Authors:  R A Branch; R J Herman
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

3.  Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.

Authors:  H H Zhou; L B Anthony; A J Wood; G R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

4.  High-performance liquid chromatographic determination of urinary 4'-hydroxymephenytoin, a metabolic marker for the hepatic enzyme CYP2C19, in humans.

Authors:  H G Xie; S L Huang; H H Zhou
Journal:  J Chromatogr B Biomed Appl       Date:  1995-06-09

5.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

Authors:  S M De Morais; G R Wilkinson; J Blaisdell; U A Meyer; K Nakamura; J A Goldstein
Journal:  Mol Pharmacol       Date:  1994-10       Impact factor: 4.436

6.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

Authors:  S M de Morais; G R Wilkinson; J Blaisdell; K Nakamura; U A Meyer; J A Goldstein
Journal:  J Biol Chem       Date:  1994-06-03       Impact factor: 5.157

7.  S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.

Authors:  S A Ward; F Goto; K Nakamura; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1987-07       Impact factor: 6.875

8.  Mephenytoin hydroxylation deficiency: kinetics after repeated doses.

Authors:  A Küpfer; P Desmond; R Patwardhan; S Schenker; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-01       Impact factor: 6.875

9.  Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.

Authors:  S M de Morais; J A Goldstein; H G Xie; S L Huang; Y Q Lu; H Xia; Z S Xiao; N Ile; H H Zhou
Journal:  Clin Pharmacol Ther       Date:  1995-10       Impact factor: 6.875

Review 10.  Biochemistry and molecular biology of the human CYP2C subfamily.

Authors:  J A Goldstein; S M de Morais
Journal:  Pharmacogenetics       Date:  1994-12
View more
  12 in total

1.  Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy--does structural design, dosing and induction strategies have a role to play?

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jul-Sep       Impact factor: 2.441

2.  Functional characterization of promoter region polymorphisms of human CYP2C19 gene.

Authors:  Uppugunduri Satyanarayana Chakradhara Rao; Anichavezhi Devendran; Kapettu Satyamoorthy; Deepak Gopal Shewade; Rajgopal Krishnamoorthy; Adithan Chandrasekaran
Journal:  Mol Biol Rep       Date:  2010-12-09       Impact factor: 2.316

3.  The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.

Authors:  Satoshi Yamada; Hideo Shiohira; Norio Yasui-Furukori; Tomonori Tateishi; Yumiko Akamine; Tsukasa Uno
Journal:  Eur J Clin Pharmacol       Date:  2013-02-24       Impact factor: 2.953

4.  MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells.

Authors:  Dianke Yu; Bridgett Green; William H Tolleson; Yaqiong Jin; Nan Mei; Yongli Guo; Helen Deng; Igor Pogribny; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2015-08-19       Impact factor: 5.858

5.  Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes.

Authors:  H Glaeser; S Drescher; M Eichelbaum; M F Fromm
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

Review 6.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  The pregnane X receptor in tuberculosis therapeutics.

Authors:  Amina I Shehu; Guangming Li; Wen Xie; Xiaochao Ma
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-12-05       Impact factor: 4.481

Review 8.  The transcriptional regulation of the human CYP2C genes.

Authors:  Yuping Chen; Joyce A Goldstein
Journal:  Curr Drug Metab       Date:  2009-07-15       Impact factor: 3.731

Review 9.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.

Authors:  Nuala Ann Helsby; Kathryn Elisa Burns
Journal:  Front Genet       Date:  2012-10-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.